TY - JOUR
T1 - American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases
T2 - Version 3
AU - Curtis, Jeffrey R.
AU - Johnson, Sindhu R.
AU - Anthony, Donald D.
AU - Arasaratnam, Reuben J.
AU - Baden, Lindsey R.
AU - Bass, Anne R.
AU - Calabrese, Cassandra
AU - Gravallese, Ellen M.
AU - Harpaz, Rafael
AU - Kroger, Andrew
AU - Sadun, Rebecca E.
AU - Turner, Amy S.
AU - Williams, Eleanor Anderson
AU - Mikuls, Ted R.
N1 - Publisher Copyright:
© 2021, American College of Rheumatology
PY - 2021/10
Y1 - 2021/10
N2 - Objective: To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID-19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). Methods: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings. Results: Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination. Conclusion: These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.
AB - Objective: To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID-19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). Methods: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings. Results: Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination. Conclusion: These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.
UR - http://www.scopus.com/inward/record.url?scp=85116061615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116061615&partnerID=8YFLogxK
U2 - 10.1002/art.41928
DO - 10.1002/art.41928
M3 - Article
C2 - 34346564
AN - SCOPUS:85116061615
SN - 2326-5191
VL - 73
SP - e60-e75
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 10
ER -